Teva Pharmaceutical Industries Quarterly Cash Flow Statement
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries free cash flow
In the quarter ended Jun 30, 2026, Teva Pharmaceutical Industries generated $411.0 million of operating cash flow and spent $104.0 million on capital expenditures. That left free cash flow of $307.0 million, a free-cash-flow margin of 7.4% of revenue. Free cash flow was up 134.4% from the prior year's $131.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -575.00M | 369.00M | 481.00M | 434.00M | 283.00M | 220.00M | -275.00M | -390.00M | -874.00M | -419.00M | 467.00M | 77.00M |
| Net Income growth (YoY) | -303.18% | +67.73% | — | — | — | — | -158.89% | -606.49% | — | — | — | +22.22% |
| Depreciation & Amortization | 241.00M | 239.00M | 260.00M | 249.00M | 251.00M | 244.00M | 269.00M | 259.00M | 259.00M | 272.00M | 266.00M | 283.00M |
| Stock-Based Compensation | 40.00M | 43.00M | 51.00M | 34.00M | 38.00M | 34.00M | 34.00M | 29.00M | 32.00M | 28.00M | 28.00M | 31.00M |
| Change in Working Capital | -164.00M | -617.00M | 229.00M | -561.00M | -336.00M | -700.00M | -245.00M | 317.00M | -10.00M | -497.00M | 292.00M | -227.00M |
| Operating Cash Flow | 411.00M | -40.00M | 1.16B | 369.00M | 227.00M | -105.00M | 575.00M | 693.00M | 103.00M | -124.00M | 1.18B | 5.00M |
| Capital Expenditures | -104.00M | -168.00M | -142.00M | -136.00M | -96.00M | -127.00M | -129.00M | -148.00M | -97.00M | -124.00M | -119.00M | -149.00M |
| Investing Cash Flow | -491.00M | 229.00M | 165.00M | 135.00M | 236.00M | 201.00M | 202.00M | 268.00M | 178.00M | 144.00M | 301.00M | 184.00M |
| Debt Issued | — | — | — | — | 2.31B | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt Repaid | — | — | 0 | -444.00M | -2.30B | -1.37B | -685.00M | 0 | -956.00M | 0 | 0 | -1.00B |
| Financing Cash Flow | -1.00M | 13.00M | 40.00M | -453.00M | 6.00M | -1.74B | -674.00M | 0 | -966.00M | -151.00M | -576.00M | -576.00M |
| Net Change in Cash | -86.00M | 185.00M | 1.35B | 42.00M | 464.00M | -1.60B | -18.00M | 1.06B | -733.00M | -236.00M | 977.00M | -420.00M |
| Free Cash Flow | 307.00M | -208.00M | 1.02B | 233.00M | 131.00M | -232.00M | 446.00M | 545.00M | 6.00M | -248.00M | 1.06B | -144.00M |
This table shows 12 quarterly periods of Teva Pharmaceutical Industries's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TEVA's reporting calendar. What is a cash flow statement?